SLNO insider transaction filings
SOLENO THERAPEUTICS INC — 49 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-05-18. Screen SLNO transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-05-18 | 4 | Huang Michael F. — Sr. VP of Clinical Development | Disposition to issuer (D): 39,823 · Disposition to issuer (D): 110,000 (derivative) · Disposition to issuer (D): 13,800 (derivative) · Disposition to issuer (D): 11,900 (derivative) | EDGAR |
| 2026-05-18 | 4 | Joshi Manher — Chief Development Officer | Disposition to issuer (D): 20,171 · Disposition to issuer (D): 72,321 (derivative) · Disposition to issuer (D): 4,700 (derivative) | EDGAR |
| 2026-05-18 | 4 | Fulk Jennifer — CHIEF FINANCIAL OFFICER | Disposition to issuer (D): 39,200 · Disposition to issuer (D): 67,660 (derivative) | EDGAR |
| 2026-05-18 | 4 | Norrett Kevin — Chief Business Officer | Disposition to issuer (D): 17,786 · Disposition to issuer (D): 64,286 (derivative) · Disposition to issuer (D): 4,000 (derivative) | EDGAR |
| 2026-05-18 | 4 | Hirano Patricia C — SEE REMARKS | Disposition to issuer (D): 22,702 · Disposition to issuer (D): 2,333 (derivative) · Disposition to issuer (D): 18,842 (derivative) · Disposition to issuer (D): 2,445 (derivative) · Disposition to issuer (D): 11,667 (derivative) · Disposition to issuer (D): 49,262 (derivative) · +4 more | EDGAR |
| 2026-05-18 | 4 | Sinclair Andrew — Director | Disposition to issuer (D): 10,491 · Disposition to issuer (D): 1,333 (derivative) · Disposition to issuer (D): 823 (derivative) · Disposition to issuer (D): 635 (derivative) · Disposition to issuer (D): 2,666 (derivative) · Disposition to issuer (D): 2,124 (derivative) · +3 more | EDGAR |
| 2026-05-18 | 4 | Volck Birgitte — Director | Disposition to issuer (D): 17,536 · Disposition to issuer (D): 1,333 (derivative) · Disposition to issuer (D): 635 (derivative) · Disposition to issuer (D): 2,666 (derivative) · Disposition to issuer (D): 2,124 (derivative) · Disposition to issuer (D): 2,666 (derivative) · +2 more | EDGAR |
| 2026-05-18 | 4 | Manning Meredith — Chief Commercial Officer | Disposition to issuer (D): 64,507 · Disposition to issuer (D): 91,000 (derivative) · Disposition to issuer (D): 29,200 (derivative) · Disposition to issuer (D): 32,800 (derivative) | EDGAR |
| 2026-05-18 | 4 | Bir Dawn Carter — Director | Disposition to issuer (D): 16,991 | EDGAR |
| 2026-05-18 | 4 | Yen Kristen — SEE REMARKS | Disposition to issuer (D): 37,639 · Disposition to issuer (D): 1,741 (derivative) · Disposition to issuer (D): 4,999 (derivative) · Disposition to issuer (D): 4,000 (derivative) · Disposition to issuer (D): 666 (derivative) · Disposition to issuer (D): 18,800 (derivative) · +6 more | EDGAR |
| 2026-05-18 | 4 | Anish Bhatnagar — CHIEF EXECUTIVE OFFICER, Director | Disposition to issuer (D): 583,656 · Disposition to issuer (D): 22,452 (derivative) · Disposition to issuer (D): 60 (derivative) · Disposition to issuer (D): 23,332 (derivative) · Disposition to issuer (D): 35,000 (derivative) · Disposition to issuer (D): 8,473 (derivative) · +6 more | EDGAR |
| 2026-05-18 | 4 | Pauls Matthew — Director | Disposition to issuer (D): 10,491 · Disposition to issuer (D): 9,063 (derivative) | EDGAR |
| 2026-05-18 | 4 | Hahn Mark W — Director | Disposition to issuer (D): 10,046 | EDGAR |
| 2026-03-31 | 4 | Huang Michael F. — Sr. VP of Clinical Development | Sale (S): 4,256 @ $30.04 · Sale (S): 1,838 @ $31.04 · Sale (S): 488 @ $31.72 | EDGAR |
| 2026-03-31 | 4 | Manning Meredith — Chief Commercial Officer | Sale (S): 4,864 @ $30.04 · Sale (S): 2,100 @ $31.04 · Sale (S): 558 @ $31.72 | EDGAR |
| 2026-03-04 | 4 | Fulk Jennifer — CHIEF FINANCIAL OFFICER | Grant/award (A): 39,200 @ $0 · Option exercise (M): 67,660 (derivative) @ $0 | EDGAR |
| 2026-01-23 | 4 | Huang Michael F. — Sr. VP of Clinical Development | Grant/award (A): 10,400 @ $0 · Grant/award (A): 11,900 (derivative) @ $0 | EDGAR |
| 2026-01-23 | 4 | Joshi Manher — Chief Development Officer | Grant/award (A): 4,100 @ $0 · Grant/award (A): 4,700 (derivative) @ $0 | EDGAR |
| 2026-01-23 | 4 | Norrett Kevin — Chief Business Officer | Grant/award (A): 3,500 @ $0 · Grant/award (A): 4,000 (derivative) @ $0 | EDGAR |
| 2026-01-23 | 4 | Hirano Patricia C — SEE REMARKS | Grant/award (A): 10,400 @ $0 · Grant/award (A): 11,900 (derivative) @ $0 | EDGAR |
| 2026-01-23 | 4 | Manning Meredith — Chief Commercial Officer | Grant/award (A): 28,600 @ $0 · Grant/award (A): 32,800 (derivative) @ $0 | EDGAR |
| 2026-01-23 | 4 | Yen Kristen — SEE REMARKS | Grant/award (A): 10,400 @ $0 · Grant/award (A): 11,900 (derivative) @ $0 | EDGAR |
| 2026-01-23 | 4 | Anish Bhatnagar — CHIEF EXECUTIVE OFFICER, Director | Grant/award (A): 114,200 @ $0 · Grant/award (A): 131,400 (derivative) @ $0 | EDGAR |
| 2026-01-23 | 4 | Mackaness James H — CHIEF FINANCIAL OFFICER | Grant/award (A): 28,600 @ $0 · Grant/award (A): 32,800 (derivative) @ $0 | EDGAR |
| 2025-12-17 | 4 | Huang Michael F. — Sr. VP of Clinical Development | Tax withholding (F): 812 @ $49.95 | EDGAR |
| 2025-12-17 | 4 | Hirano Patricia C — SEE REMARKS | Tax withholding (F): 904 @ $49.95 | EDGAR |
| 2025-12-17 | 4 | Manning Meredith — Chief Commercial Officer | Tax withholding (F): 1,922 @ $49.95 | EDGAR |
| 2025-12-17 | 4 | Yen Kristen — SEE REMARKS | Tax withholding (F): 904 @ $49.95 | EDGAR |
| 2025-12-17 | 4 | Anish Bhatnagar — CHIEF EXECUTIVE OFFICER, Director | Tax withholding (F): 7,620 @ $49.95 · Gift (G): 100,000 @ $0 | EDGAR |
| 2025-12-17 | 4 | Mackaness James H — CHIEF FINANCIAL OFFICER | Tax withholding (F): 2,013 @ $49.95 | EDGAR |
| 2025-11-19 | 4 | Norrett Kevin — Chief Business Officer | Grant/award (A): 14,286 @ $0 · Option exercise (M): 64,286 (derivative) @ $0 | EDGAR |
| 2025-11-12 | 4 | Joshi Manher — Chief Development Officer | Grant/award (A): 16,071 @ $0 · Option exercise (M): 72,321 (derivative) @ $0 | EDGAR |
| 2025-10-14 | 4 | Hahn Mark W — Director | Grant/award (A): 10,046 @ $0 | EDGAR |
| 2025-07-03 | 4 | Hirano Patricia C — SEE REMARKS | Sale (S): 3,830 @ $82.76 | EDGAR |
| 2025-06-26 | 4 | Hirano Patricia C — SEE REMARKS | Option exercise (M): 266 @ $44.25 · Sale (S): 266 @ $84.25 · Option exercise (M): 266 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | Volck Birgitte — Director | Grant/award (A): 3,991 @ $0 | EDGAR |
| 2025-06-09 | 4 | Sinclair Andrew — Director | Grant/award (A): 3,991 @ $0 | EDGAR |
| 2025-06-09 | 4 | Pauls Matthew — Director | Grant/award (A): 3,991 @ $0 | EDGAR |
| 2025-06-09 | 4 | Bir Dawn Carter — Director | Grant/award (A): 3,991 @ $0 | EDGAR |
| 2025-06-09 | 4 | Harris William G — Director | Grant/award (A): 3,991 @ $0 | EDGAR |
| 2025-04-02 | 4 | Hirano Patricia C — SEE REMARKS | Sale (S): 3,782 @ $70.11 | EDGAR |
| 2025-03-31 | 4 | Yen Kristen — SEE REMARKS | Sale (S): 1,769 @ $65.97 · Sale (S): 2,881 @ $66.79 · Sale (S): 5,239 @ $67.70 · Sale (S): 6,891 @ $68.79 · Sale (S): 3,990 @ $69.84 · Sale (S): 411 @ $70.73 · +10 more | EDGAR |
| 2025-03-31 | 4 | Pauls Matthew — Director | Option exercise (M): 5,937 @ $4.60 · Sale (S): 5,937 @ $71.55 · Option exercise (M): 5,937 (derivative) @ $0 | EDGAR |
| 2025-03-31 | 4 | Manning Meredith — Chief Commercial Officer | Sale (S): 668 @ $65.97 · Sale (S): 1,087 @ $66.79 · Sale (S): 1,976 @ $67.70 · Sale (S): 2,599 @ $68.79 · Sale (S): 1,505 @ $69.84 · Sale (S): 155 @ $70.73 · +5 more | EDGAR |
| 2025-03-31 | 4 | Huang Michael F. — Sr. VP of Clinical Development | Sale (S): 371 @ $65.97 · Sale (S): 604 @ $66.79 · Sale (S): 1,098 @ $67.70 · Sale (S): 1,444 @ $68.79 · Sale (S): 836 @ $69.84 · Sale (S): 86 @ $70.73 · +5 more | EDGAR |
| 2025-03-31 | 4 | Hirano Patricia C — SEE REMARKS | Sale (S): 1,418 @ $65.97 · Sale (S): 2,310 @ $66.79 · Sale (S): 4,199 @ $67.70 · Sale (S): 5,524 @ $68.79 · Sale (S): 3,198 @ $69.84 · Sale (S): 329 @ $70.73 · +24 more | EDGAR |
| 2025-03-31 | 4 | Anish Bhatnagar — CHIEF EXECUTIVE OFFICER, Director | Sale (S): 14,183 @ $65.97 · Sale (S): 23,095 @ $66.79 · Sale (S): 41,989 @ $67.70 · Sale (S): 55,234 @ $68.79 · Sale (S): 31,980 @ $69.84 · Sale (S): 3,291 @ $70.73 · +18 more | EDGAR |
| 2025-03-31 | 4 | Mackaness James H — CHIEF FINANCIAL OFFICER | Sale (S): 1,669 @ $65.97 · Sale (S): 2,717 @ $66.79 · Sale (S): 4,940 @ $67.70 · Sale (S): 6,498 @ $68.79 · Sale (S): 3,762 @ $69.84 · Sale (S): 387 @ $70.73 · +15 more | EDGAR |
| 2025-03-28 | 4 | Vivo Opportunity, LLC — 10% owner Vivo Opportunity Fund Holdings, L.P. — 10% owner | Sale (S): 400,000 @ $65.80 · Sale (S): 1,100,000 @ $67.80 · Sale (S): 333,557 @ $70.60 | EDGAR |
Recent 8-K events — SOLENO THERAPEUTICS INC
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-05-18 | 8-K | 1.02 — Termination of a Material Definitive Agreement 2.01 — Completion of Acquisition or Disposition of Assets 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 3.03 — Material Modification to Rights of Security Holders 5.01 — Changes in Control of Registrant 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-07 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-04-06 | 8-K | 1.01 — Entry into a Material Definitive Agreement 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-16 | 8-K | 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-26 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-25 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-23 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-12 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-04 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=SLNO returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →